Drug research

Aflibercept

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Eylea

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)NCT04592419	KOD	Phase 3	Completed	2022-06-10Actual
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.NCT04049266	KOD	Phase 2, Phase 3	Terminated	2021-11-17Actual
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152	KOD	Phase 3	Terminated	2023-05-11Actual
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368	KOD	Phase 3	Active not recruiting	2026-08Estimated
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04603937	KOD	Phase 3	Terminated	2023-04-27Actual
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationNCT06223958	OCUL	Phase 3	Active not recruiting	2026-04-29Estimated
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)NCT04964089	KOD	Phase 3	Completed	2023-03-28Actual
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918	OCUL	Phase 3	Active not recruiting	2027-01-08Estimated

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

KODCompletedPrimary completion: 2022-06-10 · Actual

Trial details

Registry ID: NCT04592419
Phase: Phase 3

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

KODTerminatedPrimary completion: 2021-11-17 · Actual

Trial details

Registry ID: NCT04049266
Phase: Phase 2, Phase 3

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

KODTerminatedPrimary completion: 2023-05-11 · Actual

Trial details

Registry ID: NCT04611152
Phase: Phase 3

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

KODActive not recruitingPrimary completion: 2026-08 · Estimated

Trial details

Registry ID: NCT06556368
Phase: Phase 3

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

KODTerminatedPrimary completion: 2023-04-27 · Actual

Trial details

Registry ID: NCT04603937
Phase: Phase 3

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

OCULActive not recruitingPrimary completion: 2026-04-29 · Estimated

Trial details

Registry ID: NCT06223958
Phase: Phase 3

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

KODCompletedPrimary completion: 2023-03-28 · Actual

Trial details

Registry ID: NCT04964089
Phase: Phase 3

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

OCULActive not recruitingPrimary completion: 2027-01-08 · Estimated

Trial details

Registry ID: NCT06495918
Phase: Phase 3

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.